Zealand, Boehringer to advance new peptide medicines
The collaboration is aimed at developing new medicines for improved treatment of patients with cardio-metabolic diseases. First agreement between the two companies was signed in June 2011, which
XtalPi has entered a strategic partnership valued at more than $400m with an international biopharmaceutical company to develop oral small-molecule therapeutics targeting a G protein-coupled receptor (GPCR).
Using GE Healthcare’s single-use WAVE Bioreactor and ReadyToProcess crossflow filtration system, the team developed a new process for the production, clarification and concentration of cytomegalovirus-like particles. Results from
The SwRI technologies employ a controlled and continuous atomizing technology that Flexion believes may facilitate efficient scale-up of Phase III clinical trial material and commercial supply. The company